Independent tracking of the pet GLP-1 drug pipeline.
GLP-1 weight-loss drugs are coming to cats and dogs, but the market is loud, confusing, and full of premature claims that a pet Ozempic already exists. It does not. We track the real science, trial by trial, and tell you exactly what is available today versus what is still years away.
Our Mission
Help owners of overweight cats and dogs understand the emerging GLP-1 drug pipeline, separate real evidence from hype, and make informed decisions with their veterinarian, without fear-based marketing or products that do not exist yet.
Roughly 61% of cats and 59% of dogs are overweight or obese. When the first pet GLP-1 medications reach the market, a lot of money and a lot of noise will follow. Our job is to be the honest, source-cited reference that gets there first and stays accurate.
How we're different
Honest about availability
No FDA-approved GLP-1 medication exists for cats or dogs as of 2026, and we never imply otherwise. We track the two active feline trials (Okava MEOW-1 and Akston AKS-562c) and report the realistic timeline: cats around 2027 to 2028, dogs around 2028 to 2030, and only if the trials succeed.
Primary sources only
Every clinical claim links to its source: trial registries, manufacturer disclosures, FDA Center for Veterinary Medicine guidance, university trial pages, or peer-reviewed veterinary research. We do not restate rumor as fact, and we date every page so you know how current it is.
Independent, not a pharma front
No investors, no pharmaceutical or veterinary parent company. Where affiliate partnerships exist (vet telehealth, prescription diets), we disclose them openly and they never dictate what we cover or how we cover it. Our incentive is to be right, because being the trusted source is the whole point.
What we cover
The feline pipeline
Okava's MEOW-1 (OKV-119 exenatide implant) and Akston's AKS-562c at Cornell, tracked trial by trial with source-cited updates.
The realistic FDA timeline
When a cat or dog GLP-1 drug could actually arrive, how FDA-CVM review works, and why the honest window is years, not months.
Pricing and availability
What pet GLP-1 is expected to cost and how it will be distributed once approved, consolidated in one place.
What works today
Vet-backed weight-loss methods, prescription diets, and free body-condition tools you can use while the drugs are still in trials.
Historical context
Slentrol, the only prior FDA-approved canine weight-loss drug (withdrawn 2013), and what its story teaches about this category.
Ozempic-for-pets reality check
Why human GLP-1 drugs are not a safe do-it-yourself option for cats or dogs, backed by species-specific risk data.
Editorial principles
Who's behind GLP-1 Pets
Iacob Pastina
Independent researcher and publisher. Builds source-cited reference sites through methodical tracking of clinical trials, regulatory filings, and the primary literature. Not a veterinarian: every clinical claim on this site links to primary sources such as trial registries, manufacturer disclosures, FDA-CVM guidance, and peer-reviewed veterinary research.
Iacob writes or edits every page on the site. GLP-1 Pets is independently operated, with no investors and no pharmaceutical or veterinary parent company. It is a sister site to GLP-1 Picks, which covers human GLP-1 telehealth.
Get in touch
Tips, corrections, or errors in our data: editor@glp1pets.com. We take corrections seriously. If we got a trial detail, a date, or a clinical fact wrong, we want to know.
Partnerships: We consider affiliate partnerships with vet telehealth and prescription-diet brands where they are genuinely useful to readers, and we disclose every one. Partnership status never changes our coverage. Same address.
Press & media: Same inbox. We respond to every email from a verified journalist within 2 business days.
Reader questions: For help assessing your pet's weight, try our dog and cat body-condition tools. Still want a human opinion? The inbox is open.